JP2005508368A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508368A5 JP2005508368A5 JP2003541772A JP2003541772A JP2005508368A5 JP 2005508368 A5 JP2005508368 A5 JP 2005508368A5 JP 2003541772 A JP2003541772 A JP 2003541772A JP 2003541772 A JP2003541772 A JP 2003541772A JP 2005508368 A5 JP2005508368 A5 JP 2005508368A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- composition
- alkyl
- composition according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34802001P | 2001-11-08 | 2001-11-08 | |
| PCT/US2002/035900 WO2003039480A2 (en) | 2001-11-08 | 2002-11-08 | Method of treating disorder related to high cholesterol concentration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005508368A JP2005508368A (ja) | 2005-03-31 |
| JP2005508368A5 true JP2005508368A5 (enExample) | 2006-01-12 |
Family
ID=23366328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003541772A Pending JP2005508368A (ja) | 2001-11-08 | 2002-11-08 | 高コレステロール濃度に関連した疾患の治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1450816A4 (enExample) |
| JP (1) | JP2005508368A (enExample) |
| CA (1) | CA2466033A1 (enExample) |
| TW (1) | TW200300078A (enExample) |
| WO (1) | WO2003039480A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7078396B2 (en) | 2001-05-03 | 2006-07-18 | Arch Development Corporation | Method of treating disorder related to high cholesterol concentration |
| WO2006047022A1 (en) | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| US8399441B2 (en) | 2004-10-25 | 2013-03-19 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis |
| US7923573B2 (en) | 2004-10-27 | 2011-04-12 | Daiichi Sankyo Company, Limited | Benzene compound having 2 or more substituents |
| MX2009005071A (es) | 2006-11-13 | 2009-05-25 | Novartis Ag | Compuestos de pirazol y triazol sustituidos como inhibidores de ksp. |
| JP2013500986A (ja) | 2009-07-29 | 2013-01-10 | ザ・ユニバーシティ・オブ・シカゴ | 肝臓ｘ受容体アゴニスト |
| US9034859B2 (en) | 2011-04-06 | 2015-05-19 | Virginia Commonwealth University | Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation |
| HUE062616T2 (hu) | 2011-09-08 | 2023-11-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, készítmények és alkalmazásaik |
| CN112057457A (zh) * | 2013-03-13 | 2020-12-11 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| FI3932932T3 (fi) | 2013-03-13 | 2025-10-15 | Sage Therapeutics Inc | Neuroaktiivisia steroideja ja niiden käyttömenetelmiä |
| JP2016193835A (ja) * | 2013-09-04 | 2016-11-17 | 学校法人常翔学園 | 核内受容体肝臓ｘ受容体アゴニスト |
| EA201990684A1 (ru) | 2013-12-24 | 2020-12-30 | Вирджиния Коммонвелт Юниверсити | Способы применения оксигенированных холестеролсульфатов (ocs) |
| JP6628745B2 (ja) | 2014-06-18 | 2020-01-15 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| WO2017007832A1 (en) | 2015-07-06 | 2017-01-12 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| PT3319611T (pt) | 2015-07-06 | 2021-04-22 | Sage Therapeutics Inc | Oxisteróis e métodos de utilização dos mesmos |
| DK3812392T3 (da) | 2015-07-06 | 2025-07-21 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| ES2921010T3 (es) | 2016-04-01 | 2022-08-16 | Sage Therapeutics Inc | Oxisteroles y procedimientos de uso de los mismos |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2018009867A1 (en) | 2016-07-07 | 2018-01-11 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| IL298681A (en) | 2016-08-02 | 2023-01-01 | Univ Virginia Commonwealth | Preparations |
| MA46351A (fr) | 2016-09-30 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols substitués en c7 et procédés en tant que modulateurs nmda |
| KR102521573B1 (ko) | 2016-10-18 | 2023-04-14 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| DK3529257T3 (da) | 2016-10-18 | 2023-08-07 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4976857A (enExample) * | 1972-12-06 | 1974-07-24 | ||
| US3963765A (en) * | 1973-04-01 | 1976-06-15 | Yehuda Mazur | Preparation of derivatives of cholesterol |
| US4217288A (en) * | 1977-03-24 | 1980-08-12 | Wisconsin Alumni Research Foundation | Anti-vitamin D compounds |
| JPS61254599A (ja) * | 1985-05-07 | 1986-11-12 | Sumitomo Pharmaceut Co Ltd | コレステロ−ルのフツ素誘導体 |
| IL105050A0 (en) * | 1992-03-27 | 1993-07-08 | Lilly Co Eli | Steroid derivatives |
| IT1255241B (it) * | 1992-07-22 | 1995-10-20 | Simos Contos | Derivato di acido biliare e suo uso in terapia |
| JP2002543216A (ja) * | 1999-04-30 | 2002-12-17 | アーチ ディベロップメント コーポレイション | ステロイド誘導体 |
| JP4309661B2 (ja) * | 2001-05-03 | 2009-08-05 | ザ ユニバーシティー オブ シカゴ | 肝臓ｘ受容体 |
-
2002
- 2002-11-08 WO PCT/US2002/035900 patent/WO2003039480A2/en not_active Ceased
- 2002-11-08 CA CA002466033A patent/CA2466033A1/en not_active Abandoned
- 2002-11-08 JP JP2003541772A patent/JP2005508368A/ja active Pending
- 2002-11-08 TW TW091132850A patent/TW200300078A/zh unknown
- 2002-11-08 EP EP02802882A patent/EP1450816A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2397168C2 (ru) | Производные тиофена в качестве ингибиторов снк 1 | |
| HRP20240157T1 (hr) | Deuterirani derivati lanifibranora | |
| RU99122697A (ru) | Фармацевтическая композиция для перорального применения производного амида n-пиперидин-3-пиразолкарбоновой кислоты, его солей и их сольватов | |
| JP2008522981A5 (enExample) | ||
| HUP0001894A2 (hu) | N-Piperidino-3-pirazolkarboxamid-származékot, sóját vagy szolvátját tartalmazó orálisan adagolható gyógyszerkészítmény | |
| JP2007502861A5 (enExample) | ||
| JP2008509166A5 (enExample) | ||
| JP2004529125A5 (enExample) | ||
| JPH08510479A (ja) | 眼の炎症障害を処置するための３‐ベンゾイルフェニル酢酸誘導体を含む局所的に投与可能な組成物 | |
| JP2003528852A5 (enExample) | ||
| EP1797878A3 (en) | Benzothiazole derivatives | |
| EP2210892A3 (en) | Neurologically-active compounds | |
| JP2002520316A5 (enExample) | ||
| JP2004532828A5 (enExample) | ||
| JP2007505044A5 (enExample) | ||
| JP2021522327A5 (enExample) | ||
| JPWO2024181437A5 (enExample) | ||
| JP2009040767A5 (enExample) | ||
| AU2017254950B2 (en) | Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein | |
| CA2589744A1 (en) | Pyrrolinidium derivatives as m3 muscarinic receptors | |
| RU2222537C2 (ru) | Новые производные морфолина, способ их получения и содержащие их фармацевтические композиции | |
| US7015238B2 (en) | Crystalline organic acid salt of amlodipine | |
| PT94347B (pt) | Processo para a preparacao de sais cristalinos de adicao a acidos da cefalosporina | |
| JP2005516066A5 (enExample) | ||
| JP2009521928A5 (enExample) |